Pharmaceuticals company Windlas Biotech announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations stood at Rs 202.7 crore as against Rs 171.3 crore, a growth of 18.3% YoY. EBITDA stood at Rs 25.5 crore as against Rs 22.0 crore YoY, a growth of 16.3% YoY. EBITDA Margin (%) came in at 12.6%. PAT stood at Rs 16.3 crore as against Rs.17.0 crore. PAT Margin (%) came in at 8.0%. FY25 Financial Highlights: Revenue from operations stood at Rs 759.9 crore as against Rs 631.0 crore, a growth of 20.4% YoY. EBITDA stood at Rs 94.1 crore as against Rs 78.2 crore YoY, a growth of 20.4% YoY. EBITDA Margin (%) came in at 12.4%. PAT stood at Rs 61.0 crore as against Rs 58.2 crore YoY, a growth of 4.8% YoY. PAT Margin (%) came in at 8.0%. Commenting on the results Hitesh Windlass, Managing Director – Windlas Biotech said, “The Indian Pharmaceutical Market (IPM) registered a YoY growth of 8.4% in FY25, largely driven by price increases with volume growth of 0.4%. We are pleased to report another quarter of strong performance of revenue growth of 20% YoY for FY25 and 18% YoY in Q4FY25. Our Generic Formulations CDMO vertical continued to benefit from new customer additions and a broader product portfolio. The Trade Generics & Institutional vertical maintained its growth momentum through wider market penetration and institutional engagement. The company continues to work towards the initiatives in the export vertical such as filing of numerous dossiers and entry into newer markets. Our proactive investments in quality systems, infrastructure, and digital transformation continue to position us strongly with respect to Schedule M compliance. We have begun utilizing Plant-2 extension in Q4 FY25 which gives us the required room for growth in upcoming period. Our Injectable facility has been approved by several large customers and few Injectable products made by us have been commercialized by our CDMO as well as Trade Generics verticals. We continue to augment our manufacturing network through modernization and retrofit of our recently acquired Plant-6 oral solids facility as per plan. The company achieved its highest-ever earnings per share (EPS) in FY25 (Rs 29.19) post listing. In line with our dividend policy, the company paid Rs 11.5 crore (Rs 5.5 per share) dividend related to FY24 and proposed the dividend of Rs 12.1 crore (Rs 5.8 per share) related to FY25. Looking ahead, we remain focused on enhancing long-term value for shareholders through diversification of client-base, increasing operational efficiencies, retaining & rewarding of key talent and expansion of dosage forms.” Adding further, Komal Gupta, CEO & CFO - Windlas Biotech said, “ We are pleased to conclude FY25 with strong performance across key metrics: Rs 759 crore. Revenue, 20.4% YoY growth 9th straight quarter of record revenue, Rs 202.7 crore. (18.3%YoY growth) Highest ever EPS of Rs 29.19 post listing Working Capital days 14 Sustained ROCE & ROE > 20% alongside capacity expansion projects Strong liquidity Rs 213 crore. We have sustained our operating margins, reflecting our robust financial management despite an increase in depreciation, largely attributable to the Injectables facility and the Plant-2 extension. PAT stood at Rs 61.0 crore for FY25 and Rs 16.3 crore for Q4FY25 – as compared to Rs 58.2 crore and Rs 17 crore for FY24. EBITDA grew by 20% YoY to Rs 94.1 crore for FY25, and by 16% YoY to Rs 25.5 crore for Q4FY25. India’s pharmaceutical industry ranks as the third-largest globally by volume. Our state-of-the-art manufacturing facilities in Dehradun strengthen our ability to deliver high-quality, scalable solutions to meet the evolving demands of the market. Windlas is strategically positioned to capture growth through diversified presence across its core verticals. In Generic Formulations CDMO vertical we continue to direct our efforts towards sustained client engagement, new client acquisitions, new product launches and higher wallet share from current partners.. This vertical recorded 15% YoY increase in FY25 to Rs 555.1 crore. For Q4FY25, this vertical generated Rs 147.2 crore in revenue, witnessing 15% YoY growth. Trade Generics and Institutional vertical is driven by portfolio expansion, broader distribution and institutional network, also supported by government driven initiatives. Our Trade Generics and Institutional vertical continued its growth momentum in FY25, with revenue surged to Rs 172.1 crore, marking a 41% YoY increase. For Q4FY25, revenue increased to Rs 45.5 crore, registering 31% growth YoY. Exports vertical reported revenue of Rs 32.6 crore in FY25, a 19% increase YoY, with Q4FY25 showing a revenue of Rs 10.0 crore reflecting 12% growth YoY. In conclusion, FY25 has been a year of meaningful progress for Windlas—anchored by consistent growth, resilient margins, and strategic execution. These results underscore the strength of our business fundamentals and the clarity of our vision. As we look ahead, we remain confident in our ability to seize emerging opportunities and deliver enduring value to all our stakeholders“ Result PDF